Literature DB >> 11155099

Complete histological regression of metastatic carcinoid tumour after treatment with octreotide.

K E Imtiaz1, P Monteith, A Khaleeli.   

Abstract

A 69-year-old woman was admitted with facial flushing, weight loss and intermittent diarrhoea. Urinary 5-hydroxyindole-acetic acid (5-HIAA) level was elevated at 200 micromol/24 h (normal: < 50). Computerized tomography (CT) demonstrated multiple enhancing liver metastases with biopsy proven carcinoid metastases with no evidence of primary tumour at this stage. Octreotide was initiated, resulting in marked improvement in carcinoid symptoms. Nine years later, she presented with abdominal pain and slightly deranged liver function tests. Repeat colonoscopy at this stage, showed an ileal tumour causing impending obstruction, necessitating urgent right hemicolectomy. Histology demonstrated primary carcinoid tumour. She continued on octreotide. Three years later at the age of 81 years, she suffered a fatal haemorrhagic stroke. Autopsy revealed complete regression of hepatic carcinoid metastases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11155099     DOI: 10.1046/j.1365-2265.2000.01126.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  6 in total

1.  The treatment of neuroendocrine tumors with long-acting somatostatin analogs: a single center experience with lanreotide autogel.

Authors:  A Bianchi; L De Marinis; A Fusco; F Lugli; L Tartaglione; D Milardi; M Mormando; A P Lassandro; R Paragliola; C A Rota; S Della Casa; S M Corsello; M G Brizi; A Pontecorvi
Journal:  J Endocrinol Invest       Date:  2011-11-07       Impact factor: 4.256

2.  Cancer: antitumor effects of octreotide LAR, a somatostatin analog.

Authors:  Kjell Oberg
Journal:  Nat Rev Endocrinol       Date:  2010-04       Impact factor: 43.330

3.  Outcomes of Pancreaticoduodenectomy for Pancreatic Neuroendocrine Tumors: Are Combined Procedures Justified?

Authors:  Cornelius A Thiels; John R Bergquist; Danuel V Laan; Kristopher P Croome; Rory L Smoot; David M Nagorney; Geoffrey B Thompson; Michael L Kendrick; Michael B Farnell; Mark J Truty
Journal:  J Gastrointest Surg       Date:  2016-02-29       Impact factor: 3.452

4.  Regression of liver metastases of occult carcinoid tumor with slow release lanreotide therapy.

Authors:  Marta Bondanelli; Maria Rosaria Ambrosio; Maria Chiara Zatelli; Luigi Cavazzini; Laura Al Jandali Rifa'y; Ettore C degli Uberti
Journal:  World J Gastroenterol       Date:  2005-04-07       Impact factor: 5.742

5.  Elevated serum ghrelin exerts an orexigenic effect that may maintain body mass index in patients with metastatic neuroendocrine tumors.

Authors:  Hank S Wang; David S Oh; Gordon V Ohning; Joseph R Pisegna
Journal:  J Mol Neurosci       Date:  2007-04-17       Impact factor: 3.444

6.  Metastatic pancreatic neuroendocrine tumor presenting as a pituitary space occupying lesion: a case report.

Authors:  Chamutal Gur; Gadi Lalazar; Asher Salmon; Victoria Dubiner; David J Gross
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.